Bolt Biotherapeutics (BOLT) Competitors $0.34 -0.03 (-6.76%) Closing price 04:00 PM EasternExtended Trading$0.34 0.00 (0.00%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock BOLT vs. FBIO, AGEN, DOMH, SABS, CRIS, MTEM, AMGN, GILD, VRTX, and REGNShould you be buying Bolt Biotherapeutics stock or one of its competitors? The main competitors of Bolt Biotherapeutics include Fortress Biotech (FBIO), Agenus (AGEN), Dominari (DOMH), SAB Biotherapeutics (SABS), Curis (CRIS), Molecular Templates (MTEM), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and Regeneron Pharmaceuticals (REGN). These companies are all part of the "biotechnology" industry. Bolt Biotherapeutics vs. Fortress Biotech Agenus Dominari SAB Biotherapeutics Curis Molecular Templates Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Fortress Biotech (NASDAQ:FBIO) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability, media sentiment and community ranking. Does the MarketBeat Community favor FBIO or BOLT? Fortress Biotech received 248 more outperform votes than Bolt Biotherapeutics when rated by MarketBeat users. Likewise, 63.69% of users gave Fortress Biotech an outperform vote while only 63.49% of users gave Bolt Biotherapeutics an outperform vote. CompanyUnderperformOutperformFortress BiotechOutperform Votes32863.69% Underperform Votes18736.31% Bolt BiotherapeuticsOutperform Votes8063.49% Underperform Votes4636.51% Do analysts rate FBIO or BOLT? Fortress Biotech currently has a consensus price target of $21.00, suggesting a potential upside of 1,286.14%. Bolt Biotherapeutics has a consensus price target of $1.13, suggesting a potential upside of 230.88%. Given Fortress Biotech's stronger consensus rating and higher possible upside, research analysts clearly believe Fortress Biotech is more favorable than Bolt Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fortress Biotech 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Bolt Biotherapeutics 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk & volatility, FBIO or BOLT? Fortress Biotech has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500. Comparatively, Bolt Biotherapeutics has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Which has better valuation and earnings, FBIO or BOLT? Fortress Biotech has higher revenue and earnings than Bolt Biotherapeutics. Fortress Biotech is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFortress Biotech$57.68M0.78-$60.64M-$2.78-0.54Bolt Biotherapeutics$7.69M1.70-$69.20M-$1.66-0.20 Is FBIO or BOLT more profitable? Fortress Biotech has a net margin of -84.53% compared to Bolt Biotherapeutics' net margin of -665.56%. Fortress Biotech's return on equity of 0.00% beat Bolt Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Fortress Biotech-84.53% N/A -34.93% Bolt Biotherapeutics -665.56%-69.46%-48.55% Does the media prefer FBIO or BOLT? In the previous week, Fortress Biotech had 1 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 3 mentions for Fortress Biotech and 2 mentions for Bolt Biotherapeutics. Bolt Biotherapeutics' average media sentiment score of 0.43 beat Fortress Biotech's score of -0.09 indicating that Bolt Biotherapeutics is being referred to more favorably in the news media. Company Overall Sentiment Fortress Biotech Neutral Bolt Biotherapeutics Neutral Do insiders & institutionals have more ownership in FBIO or BOLT? 96.5% of Fortress Biotech shares are owned by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are owned by institutional investors. 33.4% of Fortress Biotech shares are owned by insiders. Comparatively, 30.9% of Bolt Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryFortress Biotech beats Bolt Biotherapeutics on 14 of the 18 factors compared between the two stocks. Remove Ads Get Bolt Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BOLT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BOLT vs. The Competition Export to ExcelMetricBolt BiotherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.04M$6.31B$5.32B$7.60BDividend YieldN/A3.23%5.11%4.33%P/E Ratio-0.206.8021.7517.84Price / Sales1.70223.34378.5093.37Price / CashN/A65.6738.1534.64Price / Book0.115.836.444.01Net Income-$69.20M$141.86M$3.20B$247.23M7 Day Performance9.68%9.23%6.58%7.44%1 Month Performance-17.87%-12.42%-8.54%-6.13%1 Year Performance-69.91%-12.15%10.13%-0.02% Bolt Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BOLTBolt Biotherapeutics2.7113 of 5 stars$0.35-6.8%$1.13+226.1%-69.2%$13.23M$7.69M-0.2090Short Interest ↑Gap DownFBIOFortress Biotech2.4772 of 5 stars$1.57+7.5%$21.00+1,237.6%-12.8%$46.37M$57.68M-0.51170Gap UpAGENAgenus3.5019 of 5 stars$1.78+4.7%$8.75+391.6%-78.2%$45.05M$103.46M-0.16440DOMHDominari0.709 of 5 stars$3.91+1.8%N/A+37.2%$42.67M$12.59M-1.014Earnings ReportShort Interest ↑Gap DownSABSSAB Biotherapeutics3.509 of 5 stars$1.39+13.0%$11.40+720.1%-70.3%$12.91M$2.24M-0.38140Short Interest ↓Gap DownCRISCuris2.3858 of 5 stars$1.29+10.3%$21.00+1,527.9%-91.6%$10.95M$10.91M-0.1760Analyst ForecastMTEMMolecular TemplatesN/A$0.00-50.0%N/A-100.0%$1,000.00$23.48M0.00260Gap DownAMGNAmgen4.2689 of 5 stars$293.92+2.8%$314.91+7.1%+10.0%$158.03B$33.42B38.9325,200Analyst ForecastNews CoverageGILDGilead Sciences4.5339 of 5 stars$106.50+2.8%$105.12-1.3%+56.5%$132.61B$28.75B287.8417,000Positive NewsVRTXVertex Pharmaceuticals4.0986 of 5 stars$495.83+2.4%$512.41+3.3%+25.0%$127.32B$11.02B-225.386,100Short Interest ↓Analyst RevisionPositive NewsREGNRegeneron Pharmaceuticals4.8708 of 5 stars$571.06+3.0%$964.88+69.0%-36.9%$62.43B$14.20B14.9211,900Analyst ForecastPositive News Remove Ads Related Companies and Tools Related Companies Fortress Biotech Alternatives Agenus Alternatives Dominari Alternatives SAB Biotherapeutics Alternatives Curis Alternatives Molecular Templates Alternatives Amgen Alternatives Gilead Sciences Alternatives Vertex Pharmaceuticals Alternatives Regeneron Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BOLT) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bolt Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bolt Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
